BG
HZNP

Bellevue Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bellevue Group’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,411
Closed -$1.41M – 178
2022
Q4 		$1.41M Sell
12,411
-289,439
-96% -$24M 0.02% 131
2022
Q3 		$18.7M Sell
301,850
-35,584
-11% -$2.49M 0.27% 84
2022
Q2 		$26.9M Sell
337,434
-7,666
-2% -$726K 0.38% 70
2022
Q1 		$36.3M Sell
345,100
-23,500
-6% -$2.29M 0.42% 72
2021
Q4 		$39.7M Sell
368,600
-47,600
-11% -$5.19M 0.41% 74
2021
Q3 		$45.6M Sell
416,200
-1,500
-0.4% -$156K 0.46% 67
2021
Q2 		$39.1M Buy
417,700
+9,200
+2% +$847K 0.38% 82
2021
Q1 		$37.6M Buy
408,500
+28,300
+7% +$2.39M 0.4% 83
2020
Q4 		$27.8M Buy
380,200
+302,800
+391% +$22.5M 0.32% 83
2020
Q3 		$6.01M Sell
77,400
-80,800
-51% -$5.56M 0.08% 123
2020
Q2 		$8.79M Sell
158,200
-7,800
-5% -$334K 0.12% 114
2020
Q1 		$4.92M Sell
166,000
-149,700
-47% -$5.06M 0.1% 113
2019
Q4 		$11.4M Sell
315,700
-7,600
-2% -$233K 0.18% 86
2019
Q3 		$8.8M Buy
323,300
+54,800
+20% +$1.42M 0.16% 93
2019
Q2 		$6.46M Buy
268,500
+109,700
+69% +$2.78M 0.11% 101
2019
Q1 		$4.2M Sell
158,800
-9,700
-6% -$230K 0.23% 83
2018
Q4 		$3.29M Sell
168,500
-53,178
-24% -$1.04M 0.22% 84
2018
Q3 		$4.34M Buy
221,678
+30,100
+16% +$572K 0.28% 77
2018
Q2 		$3.17M Buy
+191,578
New +$2.92M 0.27% 72
2018
Q1 		– Sell
-794,062
Closed -$11.6M – 137
2017
Q4 		$11.6M Buy
794,062
+307,599
+63% +$4.32M 1.21% 34
2017
Q3 		$6.17M Buy
486,463
+79,065
+19% +$1.01M 0.65% 49
2017
Q2 		$4.84M Sell
407,398
-91,367
-18% -$1.14M 0.57% 58
2017
Q1 		$7.37M Buy
498,765
+474,765
+1,978% +$7.69M 0.98% 38
2016
Q4 		$388K Sell
24,000
-93,000
-79% -$1.69M 0.08% 114
2016
Q3 		$2.12M Hold
117,000
– – 0.38% 73
2016
Q2 		$1.93M Sell
117,000
-193,000
-62% -$3.12M 0.36% 73
2016
Q1 		$5.14M Buy
+310,000
New +$5.42M 0.93% 39

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bellevue Group's HZNP Position: Q1 2023 in Review

Bellevue Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 12,411 shares — an estimated $1.41M sold.

Bellevue Group first reported a position in HZNP in Q1 2016 and held it in 27 quarters. The position peaked at $45.6M in Q3 2021. 552 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

  • Bellevue Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
  • Bellevue Group sold 12,411 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $1.41M.
  • Bellevue Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2016 and held it in 27 quarters.
  • Bellevue Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $45.6M in Q3 2021.
  • 552 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Bellevue Group's 13F filing for Q1 2023, filed 15 May 2023.